US firm Akorn says that it has signed an active pharmaceutical ingredients supply and margin sharing agreement with Natco Pharma, located in Hyderabad, India, to commercialize two Abbreviated New Drug Application-injectable drug products.
The two ANDA drug products will focus on the anti-emetic and cancer related markets, and have a combined current market size of around $875.0 million. Under the deal, Natco will be responsible for the supply of APIs for both products, while Akorn will be responsible for the manufacturing, regulatory submissions, marketing and distribution in the hospital, clinic, and home health care markets in the USA and Canada.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze